It is indicated for the short-term treatment of duodenal ulcer, gastric ulcer and treatment of GERD
Lupin has received final approval for its Omeprazole delayed-release capsules 40 mg from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals (AstraZeneca) Prilosec delayed-release capsules 40mg.
Lupin’s Omeprazole delayed-release capsules 40 mg are the AB rated generic equivalent of AstraZeneca’s Prilosec delayed-release capsules 40mg. It is indicated for the short-term treatment of duodenal ulcer, gastric ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of erosive esophagitis and pathological hypersecretory conditions.
Comments are closed.